Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tysabri Outreach: Unified Commitment to Health

Trial Profile

Tysabri Outreach: Unified Commitment to Health

Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms TOUCH
  • Sponsors Elan Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Results assessing the role of Natalizumab extended interval dose schedule on progressive multifocal leukoencephalopathy risk (n=1472) presented at the 69th Annual Meeting of the American Academy of Neurology
    • 25 May 2016 Results (Identifying melanoma in Natalizumab treated patients through "Light Touch") at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 20 Sep 2008 As of 29 March 2008, 17883 patients have been enrolled according to an abstract presented at World Congress on Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top